The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Evaluating c-Met expression levels in tumor response to ADCs
John Strickler, MD, Duke Cancer Institute, Durham, NC, comments on the role of c-Met expression levels in predicting patient response to antibody-drug conjugates (ADCs) across tumor types. High c-Met expression often correlates with improved progression-free survival and response rates, yet ADCs may show efficacy even in patients with intermediate or low c-Met levels. Establishing optimal cut-offs for patient selection depends on therapeutic context and line of therapy, and ongoing studies aim to refine these parameters for improved patient outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
